









CLAIMS

1. A compound selected from the group consisting of:





and

, or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, being a pharmaceutically acceptable salt of the compound selected from the group consisting of:





and

,


wherein:

R^1 is -P(O)(OH)O$^-$M$^+$, -PO(O$^-$)$_2$•2M$^+$, or -PO(O$^-$)$_2$•D^{2+};


each M$^+$ is independently a pharmaceutically acceptable monovalent cation; and

D^{2+} is a pharmaceutically acceptable divalent cation.

3. The compound of claim 1, which is:



, or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1, which is:




, or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1, which is:




, or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1, which is:





, or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1, which is:



, or a pharmaceutically acceptable salt thereof.

8. A compound selected from the group consisting of:

and , or a tautomer thereof, or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to any one of claims 1-7, and a pharmaceutically acceptable excipient.

10. A pharmaceutical composition comprising the compound, or tautomer thereof, or pharmaceutically acceptable salt thereof according to claim 8, and a pharmaceutically acceptable excipient.

11. The pharmaceutical composition according to claim 9 or claim 10, formulated for oral administration.

12. The pharmaceutical composition according to claim 9 or claim 10, formulated for intravenous administration.

13. A compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof, or a compound according to claim 8 or a tautomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 9 to 12 for use in therapy.

14. A compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof, or a compound according to claim 8 or a tautomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 9 to 12 for use in treatment of pain or a pain-associated disease.

15. A compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof, or a compound according to claim 8 or a tautomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 9 to 12 for use in treatment of a Nav1.8-mediated disease, condition, or disorder.

16. Use of a compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof, or a compound according to claim 8 or a tautomer thereof or a

pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 9 to 12 in the manufacture of a medicament for treatment of pain or a pain-associated disease.

17. Use of a compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof, or a compound according to claim 8 or a tautomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 9 to 12 in the manufacture of a medicament for treatment of a Nav1.8-mediated disease, condition, or disorder.

ABSTRACT

Provided are compounds and pharmaceutical compositions and uses thereof for inhibiting $Na_v1.8$ voltage-gated sodium ion channels and treating $Na_v1.8$ mediated diseases, such as pain and pain-associated diseases, and cardiovascular diseases.